Relationship between elevated plasma ceramides and plaque rupture in patients with ST-segment elevation myocardial...

Ceramides (Cer) are an atherogenic substance. However, the associations between specific plasma Cer levels and culprit plaque morphology in ST-segment elevation myocardial infarction (STEMI) patients are unclear.

The study consisted of two parallel cohorts. 100 consecutive patients with STEMI were screened as discovery cohort. In the validation cohort, we separately screened 30 normal donors, 30 stable angina pectoris (SAP) and 315 STEMI patients. All STEMI patients underwent emergency percutaneous intervention (PCI) and optical coherence tomography (OCT) examination for culprit plaque. Based on established diagnostic criteria, STEMI patients were classified into plaque rupture (PR) and plaque erosion (PE) group, respectively. Rapid resolution liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (RRLC-Q-TOF/MS) was used to evaluate plasma Cer levels of the screened patients.

STEMI patients had higher plasma Cer(d18:1/16:0), Cer(d18:1/18:0), Cer(d18:1/24:1) and Cer(d18:1/24:0) levels than normal donors and SAP patients (p < 0.001, p < 0.001, p < 0.001, p < 0.001, respectively). Plasma Cer levels were significantly higher in STEMI patients with PR than with PE (p < 0.001, p < 0.001, p = 0.008 and p = 0.006, respectively). The frequency of PR increased with increasing tertiles of plasma Cer (adjusted p for trend = 0.004, 0.044, 0.021 and 0.133, respectively). The fully adjusted per SD odds ratios (95% confidence interval) for PR were 9.375 (2.496-35.215) for Cer(d18:1/16:0), 3.586 (1.588-8.089) for Cer(d18:1/18:0), 8.171 (1.764-37.857) for Cer(d18:1/24:1), and 3.831 (1.288-11.289) for Cer(d18:1/24:10).

The study documented novel, positive and independent associations between plasma Cer concentrations and the presence of PR, suggesting plasma Cer may act as potential biomarkers for PR to improve risk stratification.